


Formula #: 1806
Rev #:1
Date: May 8, 2024



102-2440 Canoe Ave
Coquitlam BC V3K 6C2
Canada

Nifedipine 0.3% and Lidocaine (Base) 1% in MultiMax Cream

Ingredients	Makes 100 g
Nifedipine	0.3 g
Lidocaine Base, USP	1 g
Propylene glycol	3-5 mL
Transderma MultiMax Cream Base	qs 100 g

Application:

Used for the management of pain due to anal fissures.^{1,2}

Notes:

Nifedipine is light sensitive and must be prepared with dispatch.


Lidocaine base is usually supplied as a coarse crystalline powder. Milling may be necessary to ensure a smooth final preparation.

Compounding Procedure:^{3,4}

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Accurately weigh and/or measure each ingredient
3. In a glass mortar, triturate lidocaine base until a very fine powder is obtained with no visible crystals remain.
4. In diffused light, geometrically add the nifedipine to the lidocaine powder and mix with just enough propylene glycol to form a smooth paste
5. In diffused light, geometrically incorporate the Transderma MultiMax Cream Base and bring to final weight with mixing after each addition
6. Shear force mixing (electronic mortar & pestle) and/or milling will ensure a homogenous distribution of the ingredients and facilitate the creation of a pharmaceutically elegant final preparation.
7. Package and label

Disclaimer: Xenex Laboratories Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Xenex Laboratories Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber's prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Xenex Laboratories Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.

Formula #: 1806
Rev #:1
Date: May 8, 2024



102-2440 Canoe Ave
Coquitlam BC V3K 6C2
Canada

Packaging and Labelling:

Apply exact dose topically as directed, for external use only, keep out of reach of children, apply sparingly to affected area. Store in tight, light-resistant container, keep tightly closed, protect from light and moisture. Store at controlled room temperature.


Beyond Use Date:

30 days⁴

References:

1. Nifedipine. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed August 24, 2023
2. Lidocaine. *UpToDate*. Waltham, MA.: UpToDate; 2023. www.uptodate.com. Accessed August 24, 2023
3. Nifedipine 2-mg/mL in Methylcellulose 2% Gel, Preserved. *CompoundingToday*. Edmond, OK. International Journal of Pharmaceutical Compounding; 2022. www.compoundingtoday.com. Accessed August 24, 2023
4. Gabapentin 6%, Ketamine 10% and Nifedipine 2% in Pluronic™ Lecithin Organogel. *CompoundingToday*. Edmond, OK. International Journal of Pharmaceutical Compounding; 2022. www.compoundingtoday.com. Accessed August 24, 2023
5. National Association of Pharmacy Regulatory Authorities, Guidance Document for Pharmacy Compounding of Non-Sterile Preparations. June 2018

Signed By:

 , Pharm.D.

Reviewed by:

Paul Gibbons B.Sc. Pharm. RPh. 29 August 2023

Disclaimer: Xenex Laboratories Inc. has provided the formula and instructions above as a model for educational purposes only on the basis of recognized compendia and texts or references. Xenex Laboratories Inc. takes no responsibility for the validity or accuracy of this information or for its safety or effectiveness, nor for any use thereof, which is at the sole risk of the licensed pharmacist. Adjustments may be needed to meet specific patient needs and in accordance with a licensed prescriber's prescription. The pharmacist must employ appropriate tests to determine the stability of this suggested formula. Xenex Laboratories Inc., its owners, officers, agents, contractors, affiliates and employees cannot be held liable to any person or entity concerning claims, loss or damage caused by, or alleged to be caused by, directly or indirectly, the use or misuse of the information contained in this suggested formula. In all cases, it is the responsibility of the licensed pharmacist to know the law, to compound any finished product and to dispense these products in accordance with Health Canada and FDA guidelines and appropriate Provincial Drug Schedules and Provincial or Territorial Pharmacy Practice Standards.